We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Top Buys
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
176
DELISTED
Merus
MRUS
| – | – |
-69,025
| Closed | -$1.27M |
|
177
Option Care Health
OPCH
$3.48B
| – | – |
-64,975
| Closed | -$2.06M |
|
178
Ultragenyx Pharmaceutical
RARE
$2.96B
| – | – |
-67,065
| Closed | -$2.69M |
|
179
Syndax Pharmaceuticals
SNDX
$2.03B
| – | – |
-117,717
| Closed | -$2.49M |
|
180
Travere Therapeutics
TVTX
$5.05B
| – | – |
-418,520
| Closed | -$9.41M |
|
181
Zai Lab
ZLAB
$2.34B
| – | – |
-34,640
| Closed | -$1.15M |
|
|
CTLT
182
DELISTED
CATALENT, INC.
CTLT
| – | – |
-49,406
| Closed | -$3.25M |
|
|
VECT
183
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-682,834
| Closed | -$5.87M |
|
|
RXDX
184
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-50,538
| Closed | -$5.42M |
|
|
CSII
185
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-174,859
| Closed | -$3.47M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM